In March, we filed our Reg. A Offering Statement with the Securities and Exchange Commission, and it is now under active review. Qualification of our offering by the SEC is anticipated in a few weeks. Until then, a "Testing the Waters" campaign is underway on the SeedInvest portal. We have already received over $800,000 in investment "reservations" since launching the campaign about 2 weeks ago.

There are several advantages of investing in a Reg. A+ offering (vs. a traditional private placement), including more transparency and liquidity. For more on this please read " Three Big Advantages of Investing in a Reg. A+ Qualified Company ".

If you are considering making an investment in 20/20, please make a non-binding reservation today. By reserving shares you will have the opportunity to invest ahead of the public launch.

The Maryland Biotechnology Investor Tax Credit has for many years provided a more than 50% refund to over 200 investors in our company. Most of these investors reside outside of Maryland. This year, we were successful in advancing to the front of the state's on-line application queue so that we are now confident that at least $2 million invested in 20/20 going forward will receive the state & county guaranteed 55% cash refund.

Accredited investors interested in investing between $25,000 and $500,000 in 20/20 with a guaranteed 55% refund should contact us immediately at investors@2020gene.com or call 240-453-6339 x102. Our tax credit rounds typically oversubscribe quickly.

In Q2 we acquired, installed, validated, and were trained to operate a new, state-of-the art immunoassay analyzer from Roche Diagnostics.   This instrument is expected to deliver a high degree of diagnostic accuracy and reliability while reducing labor and reagent costs. Using a comparable analyzer to those used in thousands of hospital laboratories worldwide, as well as by large reference labs like Quest Diagnostics and LabCorp, permits us to utilize data from parts of the world where biomarkers are more commonly tested for cancer screening than here in the U.S. To demonstrate this, we compared OneTest biomarker results from blood samples of 30 Americans tested both in our lab and shipped frozen to a lab in Taiwan and found an approximate 98% correlation for each biomarker!

Upon final compliance with all CLIA laboratory regulations and inspections, we anticipate being able to run OneTest by the end of July.

For many years, 20/20's patented BioCheck kits have been the first tool used by hundreds of first responder organizations around the world when confronting suspicious powders feared to potentially contain a deadly bio-threat agent. This quarter, we saw new BioCheck customers ordering from Korea, Germany, and the U.S. contributing to a 10% revenue increase in the 1st half of '18 compared to the same period last year. "20/20 Kits" as they are commonly called are popular and respected within this community of first responders.

Two years ago, the results of a 5 year federal government study were reported, concluding that fire fighters showed higher rates of several types of cancer than the general U.S. population, especially digestive, oral, respiratory, and urinary cancers. There were even more cases of certain cancers among younger fire fighters.

Last month at an International Assoc. of Fire Chiefs Hazardous Materials conference, we began to promote both BioCheck and OneTest at the same exhibition booth. We anticipate increased promotion of OneTest for fire fighters in the 2nd half of this year. 

New hires in Q2 included Mary An Woo as 20/20's Taiwan Commercial Director. In light of our research relationship with Taiwan's largest hospital group, we are using Taiwan as a beachhead for Greater China and the Far East. Previously, Mary An served as the Director of Maryland's business center in Taiwan.

Other recent new hires include two Sales Associates for OneTest, one with experience in healthcare product sales and the other in public health. In Q3 and Q4, we expect additional new hires in Sales & Marketing and Data Science.

We will be holding a meeting for current shareholders, prospective investors, and others interested in learning about our blood tests for early detection of cancers. The event will begin at 5:30 p.m. on Wednesday August 1. in downtown Washington, D.C. at the location linked below.

Text Link